2 news items
Sage Therapeutics Expects Cash & Equivalents Plus Funding To Support Its Operations Into 2026; Expects ZULRESSO Revenues To Continue To Decrease Over Time
SAGE
25 Apr 24
for women with PPD, the Company anticipates ZULRESSO revenues will continue to decrease over time.
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
SAGE
25 Apr 24
Payor coverage now in place for a majority of commercially covered lives for ZURZUVAE in the treatment of women with postpartum depression (PPD
- Prev
- 1
- Next